|
|
CHDI, Inc. is actively engaged in partnering with leading biopharmaceutical companies and translational contract research organizations (CROs).
Together with High Q and HPTF, we also fund academic research.
|
General Terms
Our overall objective is to keep promising compounds moving to the market as quickly as possible.
- Non-dilutive, non-equity financing.
- Contract based - paid upon achievement of specific milestones.
- CHDI retains R&D rights for HD.
- HD should be the first indication pursued and CHDI retains march-in provisions for abandoned HD programs.
- CHDI may seek to participate in HD upside (to support future research) if funding reaches a significant level but partner generally retains rights to indications other than HD.
- Terms flexible - may vary based on the unique nature of each proposal.
- We seek to preserve our partners IP while balancing the need to share relevant results with other HD investigators.
Market Potential
HD is a progressive, neurodegenerative disease with no approved therapy.
- Incidence: 35,000 patients in the U.S.
- Genetic Risk: 175,000 carriers
- Average age of onset: 37
- Survival: 10-15 years
Estimated Market size of over $500M in the US and nearly $1 Billion globally (Source: Visiongain report, 2003)
Please contact Tom Base (
) at 310.342.5512.
|
|
